A high-throughput selection system for fast-acting covalent protein drugs
Science · 2026
DOI: 10.1126/science.adv3081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2026. Verfasst von Qiongxuan Fan und 13 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Cell Surface Display Techniques, Drug Discovery, Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Westlake Education Foundation, The Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Covalent protein drugs offer therapeutic potential but are limited by slow target engagement and the absence of high-throughput selection platforms. Rapid covalent binding requires coordinated optimization of affinity, stability, and warhead geometry, which is an intrinsically multidimensional challenge. We developed a yeast display platform coupled with chemoselective modification that enables selection of fast-acting covalent proteins without increasing intrinsic warhead reactivity. Using this system, we engineered a covalent programmed death-ligand 1 (PD-L1) antagonistic nanobody with rapid cross-linking kinetics [observed rate constant ( k obs ) = 0.18 min −1 , half-life ( t 1/2 ) = 3.8 min] and improved tumor suppression compared with envafolimab and atezolizumab. Similarly, we engineered a fast-acting covalent interleukin-18 ( k obs = 0.54 min −1 , t 1/2 = 1.3 min) and a covalent miniprotein targeting the receptor binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), demonstrating applicability across protein modalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, China.
- Research Center for Industries of the Future and Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
- Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China.
- Institute of Biology, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China.
- School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
- Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, China.
ORCID-Profile: Qiongxuan Fan, Jiahao Mei, Tian Li, Chuanlong Zang, Mengjiao Li, Jing Tang, You Xu, Ge Yu, Kai Chen, Bing Yang, Jing Huang, Ting Zhou, Bobo Dang
Förderung
- Westlake Education Foundation
- The Natural Science Foundation of China
- National Key Research and Development Program of China
- Westlake Laboratory of Life Sciences and Biomedicine
- Pioneer and Leading Goose R&D Program of Zhejiang
- Research Center for Industries of the Future (RCIF) at Westlake University
Zitieren
APA
Fan, Q., Mei, J., Li, T., Zang, C., Li, M., Tang, J., Xu, Y., Yu, G., Liu, D., Chen, K., Yang, B., Huang, J., Zhou, T., & Dang, B. (2026). A high-throughput selection system for fast-acting covalent protein drugs. Science. https://doi.org/10.1126/science.adv3081
Vancouver
Fan Q, Mei J, Li T, Zang C, Li M, Tang J, et al. A high-throughput selection system for fast-acting covalent protein drugs. Science. 2026. doi:10.1126/science.adv3081
BibTeX
@article{Fan2026,
author = {Fan, Qiongxuan and Mei, Jiahao and Li, Tian and Zang, Chuanlong and Li, Mengjiao and Tang, Jing and Xu, You and Yu, Ge and Liu, Dandan and Chen, Kai and Yang, Bing and Huang, Jing and Zhou, Ting and Dang, Bobo},
title = {A high-throughput selection system for fast-acting covalent protein drugs},
journal = {Science},
year = {2026},
doi = {10.1126/science.adv3081}
}
EUVIMED